BNET Industries
amylin pharmaceuticals inc. - All News and Analysis
Will Carl Icahn Come to Amylin's Rescue?
Seeking Alpha
- 2008-11-17
Mike Huckman submits: Wall Street has essentially thrown in the towel lately on Amylin Pharmaceuticals AMLN. The shares have plummeted from nearly $30 just three months ago to around $7 yesterday. But billionaire activist investor Carl Icahn apparently sees the stock as being on sale. At the end...
Amylin Facing Crisis of Confidence
Seeking Alpha
- 2008-11-14
EP Vantage submits: The plunge in Amylin’s AMLN valuation over the last few months indicates a serious collapse in confidence in the group as a whole, and with a focus on diabetes and obesity, two of the most challenging areas of drug development at the moment, it is not hard...
Zacks Analyst Blog Highlights: Schlumberger Ltd., Amylin Pharmaceuticals, Inc., Eli Lilly & Co., Onyx Pharmaceuticals, Inc. and Diageo Plc
- 2008-10-23
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Schlumberger Ltd. (NYSE: SLB), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly...
Amylin Pharmaceuticals Inc. Q3 2008 Earnings Conference Call Transcript
Seeking Alpha
- 2008-10-21
Question-and-Answer Session[Operator Instructions]. Your first question comes from the line of Thomas Wei from Piper Jaffray. Thomas Wei - Piper Jaffray Just a housekeeping question about the sales for the quarter were actually about better than what the IMS data would have suggested any one time factors there? And...
Zacks Analyst Blog Highlights: Epicor Software Corp., Amylin Pharmaceuticals, Inc., CNOOC Ltd., Skyworks Solutions, Inc. and Nokia Corp
- 2008-10-02
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Epicor Software Corp. (Nasdaq: EPIC), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), CNOOC...
Thursday Options Outlook: LEH, MER, GE, PTIE, AMLN, UNH, DBA
Seeking Alpha
- 2008-09-11
Rebecca Engmann Darst co-authored this article. Lehman Brothers LEH – Caught at the very center of this Jupiter’s storm in volatility is, of course, Lehman Brothers, whose fight for survival has incited so much of the sector’s turbulence in recent sessions. Shares have taken back some early losses after struggling...
Eli Lilly's Brewing Battle With Bristol-Myers
Seeking Alpha
- 2008-09-07
Mike Huckman submits: Last week I blogged about Eli Lilly's LLY "Coming Soon" banner ad I spotted in the online edition of The New England Journal of Medicine. It's designed to generate buzz about the company's crucial new bloodthinner that could win Food and Drug Administration approval this month....
Five Presentations from the Recent Biotech Investment Conference
Seeking Alpha
- 2008-09-05
Mike Huckman submits: Medivation's Presentation: Standing Room Only A little more than 24 hours after announcing its big, lucrative Alzheimer's drug partnership with Pfizer PFE, Medivation MDVN had the lead-off position (I wonder if they told organizers they'd be a newsmaker) at yesterday's BioCentury/Thomson Reuters biotech investment conference...
Zacks Analyst Blog Highlights: Sappi Ltd., Amylin Pharmaceuticals Inc., Eli Lilly and Co., Rudolph Technologies, Inc. and Tesoro Corp
- 2008-08-28
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sappi Ltd. (NYSE: SPP), Amylin Pharmaceuticals Inc. (Nasdaq: AMLN), Eli Lilly...
Five Biopharma Companies Drop on Negative Drug News
Seeking Alpha
- 2008-08-28
Mike Huckman submits: Within a 12-hour period five biopharma companies revealed negative drug news that is sending their stocks lower -- in the case of Amylin Pharmaceuticals AMLN and Cell Genesys CEGE, much lower. After the closing bell Tuesday, Bristol-Myers Squibb BMY and Pfizer PFE announced a bloodclot drug...
Wednesday Options Update: LEH, AMLN, XLE, NTAP, CLNE, HOS, DLTR, TEL, ESI
Seeking Alpha
- 2008-08-27
Rebecca Engmann Darst contributed to this report. Lehman Brothers LEH – A more positive tone for Lehman’s today has shares knocking on the door of the $15.00 mark having rallied by 6.3% so far Wednesday. Options volume puts Lehman’s on our scanner of most actively traded equity options today....
Amylin, Lilly: Another Case of a Panic Driven Sell-Off
Seeking Alpha
- 2008-08-27
A. Reza Saadat submits: On Tuesday August 26, Amylin AMLN and its partner Eli Lilly LLY announced that four patients had died while on diabetes treatment Byetta.Both Amylin (down 12%) and Lilly (down 1%) sold off in after hours following repeated headlines saying Byetta was responsible for the...
Drug Safety Updates For Elan, Biogen, Amylin, and Lilly
Seeking Alpha
- 2008-08-27
Mike Huckman submits: After the closing bell Monday, Eli Lilly LLY and Amylin Pharmaceuticals AMLN announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Last week, the Food and Drug Administration revealed that six patients on the drug had to...
Amylin Shares Gain Ground on Outlook for Byetta
Seeking Alpha
- 2008-08-26
Trader Mark submits: I've been stating for a while now that this market has changed character - even as the bear market hit us in the winter we were still able to find pockets of strength where buying breakouts were rewarded. However, at this time, instead of buying breakouts, the...
Wednesday Options Update: MER, BAC, FNM, AMGN, AMLN, LLY, MEA, GE
Seeking Alpha
- 2008-08-20
Rebecca Engmann Darst contributed to this report. Merrill Lynch MER – Financial shares started the day on shaky footing following Goldman Sachs’ downgrade of profit estimates and share price targets for a slew of banks and brokerages, leaving traders understandably wary of what’s waiting behind the proverbial Door #3....
Why I'm Buying Amylin Now
Seeking Alpha
- 2008-08-20
Trader Mark submits: I'm following the "buy the busted stocks" instead of breakouts methodology, but breaking a rule on buying individual biotech stocks with today's purchase of Amylin Pharmaceuticals AMLN. This is one of the few biotechs I know pretty well, and have followed for quite a while - mostly...
AstraZeneca Gives FluMist Spray a Shot in the Arm
Seeking Alpha
- 2008-08-19
Mike Huckman submits: Ads for flu vaccines have traditionally been confined to public service announcements PSAs, health and media alerts. So, that's why I was surprised to see this colorful full-page ad in The New York Times last weekend for FluMist from AstraZeneca AZN/MedImmune. by Mike Huckman
5 Potential Buyout Targets in Biotech - Barron's
Seeking Alpha
- 2008-08-17
Bristol-Myers Squibb BMY made a $4.5B bid for the shares of ImClone IMCL it doesn't already own. Roche Holdings (RHHBY.PK) made a $44B offer for the shares of Genetech DNA it doesn't own. Both targets want the bid prices raised. Barron's Lawrence Strauss says these are just the two latest...
My Model Biotech Picks: What's Hot and What's Not
Seeking Alpha
- 2008-08-13
A. Reza Saadat submits: Analyzing the performance of my previous picks is by far my favorite part of writing this blog. It has on many occasions allowed be to learn from my mistakes.I have moved the numbers to Google docs so that they are easier to read. Here is...
Icahn Racks Up Gains in ImClone, Motorola, and Amylin
Seeking Alpha
- 2008-08-01
Lon Juricic submits: Activist investor Carl Icahn had a nice day yesterday. Here's why:Bristol-Myers BMY sent Mr. Icahn a letter presenting a $60 per share offer for ImClone Systems IMCL. Icahn is the Chairman of ImClone, and owns 11,669,544 shares of the biotech company. With shares of ImClone...
Sort byClose
View by Content TypeClose
View by Related Tag Close
- Biotech (11 results)
- Eli Lilly & Co. (11 results)
- Healthcare (8 results)
- Nasdaq Stock Market Inc. (5 results)
- Bristol-Myers Squibb Co. (5 results)
- Investment (4 results)
- FINANCE (4 results)
- stock (4 results)
- New York Stock Exchange (3 results)
- Seeking Alpha (3 results)
- Celgene Corp. (3 results)
- ImClone Systems Inc. (3 results)
- US Market (3 results)
- Pfizer Inc. (3 results)
- blog (3 results)
- Incorporated: 1987
- CEO: Mr. Daniel M. Bradbury
Amylin Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Co. is engaged in selling BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection for the treatment of patients with diabetes. As of Dec 31 2007, Co. had ongoing programs in pharmaceutical discovery and development, including a late-stage program to develop exenatide once weekly, to enable once weekly administration of exenatide for the treatment of type 2 diabetes, as well as other early stage programs for diabetes, obesity and other therapeutic areas.
Competitors
Stock Quote
Board of Directors
Mr. Joseph C. Cook Jr. Chairman
Dr. Jay S. Skyler M.D.
Mr. Joseph P. Sullivan
Mr. James N. Wilson
Mr. Daniel M. Bradbury
Mr. Adrian Adams
Mr. Steven R. Altman
Ms. Teresa Beck
Ms. Karin Eastham
Dr. James R. Gavin III, M.D
Ms. Ginger L. Graham
Mr. Howard E. Greene Jr.
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q09 (Qtr End 11/30/08) Earnings Call Transcript
on Jan 06, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q09 (Qtr End 11/30/08) Earnings Call Transcript
on Dec 16, 2008about WNI
-
AVANIR Pharmaceuticals F4Q08 (Qtr End 10/31/08) Earnings Call Transcript
on Dec 15, 2008about AVNR
-
Martek Biosciences Corporation F4Q08 (Qtr End 10/31/08) Earnings Call Transcript
on Dec 11, 2008about MATK
-
Peregrine Pharmaceuticals F2Q09 (Qtr End 10/31//08) Earnings Call Transcript
on Dec 10, 2008about PPHM
